Showing results (4151-4160 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|March 28, 2025
Dynamics of hyperglycemia of patients treated with alpelisib: exploratory interim analysis of ITACA trialMarija Pancirov, Josipa Flam, Jelena Šuto Pavičić, et al.
The Oncologist|April 11, 2025
Outcomes for recurrent or metastatic head and neck cancer by HPV status: a systematic review and meta-analysisJong Chul Park, Geun Hee Ye, Ross Merkin, et al.
The Oncologist|April 7, 2025
Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States: an observational cohort studyClara Lam, Della Varghese, Jenna Collins, et al.
The Oncologist|March 20, 2025
Development of tele-lifestyle-based multidisciplinary survivorship program for gynecologic oncology practiceNathalie D McKenzie, Nnamdi I Gwacham, Julie W Pepe, et al.
The Oncologist|March 20, 2025
Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case reportAntonio Vitale, Emanuele Vita, Alessio Stefani, et al.
The Oncologist|March 10, 2025
Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinomaI-Wei Ho, Nai-Jung Chiang, Jiun-I Lai, et al.
The Oncologist|March 10, 2025
"Incidentally" discovered Von Hippel Lindau disease: an emerging clinical phenotypeMichael N Trinh, Lauren Bear, Brian V Nahed, et al.
The Oncologist|March 10, 2025
Response to pembrolizumab in advanced prostate cancer with predictive biomarkersNicole J Altomare, Yutai Li, Clayton Neill, et al.
The Oncologist|March 4, 2025
Management of vasomotor symptoms in cancer patientsLing Zhu, Tammy T Hshieh, Tara K Iyer, et al.
The Oncologist|March 4, 2025
Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP)Erick F Saldanha, Vladmir C Cordeiro de Lima, Aline Fares, et al.
Pageof 571